These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 28640531)

  • 1. Apparent diffusion coefficient in estrogen receptor-positive and lymph node-negative invasive breast cancers at 3.0T DW-MRI: A potential predictor for an oncotype Dx test recurrence score.
    Thakur SB; Durando M; Milans S; Cho GY; Gennaro L; Sutton EJ; Giri D; Morris EA
    J Magn Reson Imaging; 2018 Feb; 47(2):401-409. PubMed ID: 28640531
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of diffusion weighted imaging as supplement to dynamic contrast enhanced breast MRI: Can it help predict malignancy, histologic grade and recurrence?
    Roknsharifi S; Fishman MDC; Agarwal MD; Brook A; Kharbanda V; Dialani V
    Acad Radiol; 2019 Jul; 26(7):923-929. PubMed ID: 30293819
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitative apparent diffusion coefficient measurement obtained by 3.0Tesla MRI as a potential noninvasive marker of tumor aggressiveness in breast cancer.
    Durando M; Gennaro L; Cho GY; Giri DD; Gnanasigamani MM; Patil S; Sutton EJ; Deasy JO; Morris EA; Thakur SB
    Eur J Radiol; 2016 Sep; 85(9):1651-8. PubMed ID: 27501902
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diffusion-weighted MRI characteristics associated with prognostic pathological factors and recurrence risk in invasive ER+/HER2- breast cancers.
    Amornsiripanitch N; Nguyen VT; Rahbar H; Hippe DS; Gadi VK; Rendi MH; Partridge SC
    J Magn Reson Imaging; 2018 Jul; 48(1):226-236. PubMed ID: 29178616
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of diffusion-weighted MRI: predicting axillary lymph node metastases in breast cancer.
    Chung J; Youk JH; Kim JA; Gweon HM; Kim EK; Ryu YH; Son EJ
    Acta Radiol; 2014 Oct; 55(8):909-16. PubMed ID: 24234236
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diffusion-weighted MRI of estrogen receptor-positive, HER2-negative, node-negative breast cancer: association between intratumoral heterogeneity and recurrence risk.
    Kim JY; Kim JJ; Hwangbo L; Lee JW; Lee NK; Nam KJ; Choo KS; Kang T; Park H; Son Y; Grimm R
    Eur Radiol; 2020 Jan; 30(1):66-76. PubMed ID: 31385051
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Convolutional Neural Network Using a Breast MRI Tumor Dataset Can Predict Oncotype Dx Recurrence Score.
    Ha R; Chang P; Mutasa S; Karcich J; Goodman S; Blum E; Kalinsky K; Liu MZ; Jambawalikar S
    J Magn Reson Imaging; 2019 Feb; 49(2):518-524. PubMed ID: 30129697
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlations between apparent diffusion coefficient values of invasive ductal carcinoma and pathologic factors on diffusion-weighted MRI at 3.0 Tesla.
    Park SH; Choi HY; Hahn SY
    J Magn Reson Imaging; 2015 Jan; 41(1):175-82. PubMed ID: 24353241
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predicting metastasis in clinically negative axillary lymph nodes with minimum apparent diffusion coefficient value in luminal A-like breast cancer.
    Kato F; Kudo K; Yamashita H; Baba M; Shimizu A; Oyama-Manabe N; Kinoshita R; Li R; Shirato H
    Breast Cancer; 2019 Sep; 26(5):628-636. PubMed ID: 30937834
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diffusion-weighted imaging (DWI) with apparent diffusion coefficient (ADC) mapping as a quantitative imaging biomarker for prediction of immunohistochemical receptor status, proliferation rate, and molecular subtypes of breast cancer.
    Horvat JV; Bernard-Davila B; Helbich TH; Zhang M; Morris EA; Thakur SB; Ochoa-Albiztegui RE; Leithner D; Marino MA; Baltzer PA; Clauser P; Kapetas P; Bago-Horvath Z; Pinker K
    J Magn Reson Imaging; 2019 Sep; 50(3):836-846. PubMed ID: 30811717
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnostic Usefulness of Combination of Diffusion-weighted Imaging and T2WI, Including Apparent Diffusion Coefficient in Breast Lesions: Assessment of Histologic Grade.
    Kim KW; Kuzmiak CM; Kim YJ; Seo JY; Jung HK; Lee MS
    Acad Radiol; 2018 May; 25(5):643-652. PubMed ID: 29339079
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multiparametric diffusion-weighted imaging in breast lesions: Association with pathologic diagnosis and prognostic factors.
    Suo S; Cheng F; Cao M; Kang J; Wang M; Hua J; Hua X; Li L; Lu Q; Liu J; Xu J
    J Magn Reson Imaging; 2017 Sep; 46(3):740-750. PubMed ID: 28139036
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radiological predictive factors on preoperative multimodality imaging are related to Oncotype DX recurrence score in estrogen-positive/human epidermal growth factor receptor 2-negative invasive breast cancer: a cross-sectional study.
    Tsukada H; Tsukada J; Ochi T; Noguchi E; Okamoto T
    Ann Nucl Med; 2022 Oct; 36(10):853-864. PubMed ID: 35819628
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diffusion-weighted imaging and (18) F-fluorodeoxyglucose positron emission tomography/computed tomography in breast cancer: Correlation of the apparent diffusion coefficient and maximum standardized uptake values with prognostic factors.
    Karan B; Pourbagher A; Torun N
    J Magn Reson Imaging; 2016 Jun; 43(6):1434-44. PubMed ID: 26663655
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association between partial-volume corrected SUVmax and Oncotype DX recurrence score in early-stage, ER-positive/HER2-negative invasive breast cancer.
    Lee SH; Ha S; An HJ; Lee JS; Han W; Im SA; Ryu HS; Kim WH; Chang JM; Cho N; Moon WK; Cheon GJ
    Eur J Nucl Med Mol Imaging; 2016 Aug; 43(9):1574-84. PubMed ID: 27209424
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nomogram update based on TAILORx clinical trial results - Oncotype DX breast cancer recurrence score can be predicted using clinicopathologic data.
    Orucevic A; Bell JL; King M; McNabb AP; Heidel RE
    Breast; 2019 Aug; 46():116-125. PubMed ID: 31146185
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dynamic contrast-enhanced and diffusion-weighted MRI of invasive breast cancer for the prediction of sentinel lymph node status.
    Choi EJ; Youk JH; Choi H; Song JS
    J Magn Reson Imaging; 2020 Feb; 51(2):615-626. PubMed ID: 31313393
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Histogram analysis of volume-based apparent diffusion coefficient in breast cancer.
    Park GE; Kim SH; Kim EJ; Kang BJ; Park MS
    Acta Radiol; 2017 Nov; 58(11):1294-1302. PubMed ID: 28273747
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlations between apparent diffusion coefficient values and prognostic factors of breast cancer.
    Kamitani T; Matsuo Y; Yabuuchi H; Fujita N; Nagao M; Jinnouchi M; Yonezawa M; Yamasaki Y; Tokunaga E; Kubo M; Yamamoto H; Yoshiura T; Honda H
    Magn Reson Med Sci; 2013; 12(3):193-9. PubMed ID: 23857151
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Breast cancer-specific survival in patients with lymph node-positive hormone receptor-positive invasive breast cancer and Oncotype DX Recurrence Score results in the SEER database.
    Roberts MC; Miller DP; Shak S; Petkov VI
    Breast Cancer Res Treat; 2017 Jun; 163(2):303-310. PubMed ID: 28243896
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.